UK biotech exploits microgravity to privatise drug innovation, obscuring terrestrial inequities in cancer care access
Original framing: “Final frontier for meds? UK startup sends drug-making into space” — The Guardian - Technology
Marginalised communities—particularly in LMICs—are the most affected by cancer disparities yet have the least access to cutting-edge treatments. Their exclusion from drug development processes perpetuates cycles of inequity, as seen in the underrepresentation of Black patients in clinical trials for decades. The narrative’s focus on space-based solutions ignores the fact that many existing drugs could be repurposed or reformulated to reduce costs and improve accessibility.
The BioOrbit narrative exemplifies how neoliberal innovation systems prioritise spectacle over substance, framing space as the 'final frontier' for medicine while ignoring the terrestrial frontiers of equity and accessibility.
This approach reflects a broader pattern in global health, where high-tech solutions are celebrated while systemic inequities—rooted in colonial legacies, patent monopolies, and underfunded public health systems—are obscured. Cross-culturally, the focus on crystallised proteins overlooks the proven efficacy of traditional medicines and holistic healing models, which have addressed cancer and other diseases for centuries without reliance on orbital laboratories. The trickster’s lens reveals the absurdity of privatising the cosmos for drug development when millions lack access to basic treatments, highlighting the need for open-source innovation, benefit-sharing with indigenous knowledge holders, and decentralised care networks. True progress requires dismantling the power structures that treat health as a commodity and instead centering the voices and needs of those most affected by disease.